NO932344L - Kinoksalinderivater med affinitet for quisqualatreseptorer - Google Patents

Kinoksalinderivater med affinitet for quisqualatreseptorer

Info

Publication number
NO932344L
NO932344L NO93932344A NO932344A NO932344L NO 932344 L NO932344 L NO 932344L NO 93932344 A NO93932344 A NO 93932344A NO 932344 A NO932344 A NO 932344A NO 932344 L NO932344 L NO 932344L
Authority
NO
Norway
Prior art keywords
affinity
quisqualate receptors
kinoxalin
derivatives
kinoxalin derivatives
Prior art date
Application number
NO93932344A
Other languages
English (en)
Other versions
NO932344D0 (no
NO304693B1 (no
Inventor
Andreas Huth
Ralph Schmiechen
Ilse Beetz
Ingrid Schumann
Lechoslaw Turski
Peter Andreas Loeschmann
David Norman Stephens
Dieter Seidelmann
Martin Krueger
Dieter Rahtz
Peter Hoelscher
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4135871A external-priority patent/DE4135871A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO932344D0 publication Critical patent/NO932344D0/no
Publication of NO932344L publication Critical patent/NO932344L/no
Publication of NO304693B1 publication Critical patent/NO304693B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/650952Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO932116A 1991-10-26 1993-06-25 Kinoksalinderivater med affinitet for quisqualatreseptorer NO304693B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4135871A DE4135871A1 (de) 1991-10-26 1991-10-26 Chinoxalinderivate, deren herstellung und verwendung in arzneimitteln
DE4224200 1992-07-17
PCT/DE1992/000895 WO1993008173A1 (de) 1991-10-26 1992-10-25 Chinoxalin-derivate, mit affinität an die quisqualat-rezeptoren

Publications (3)

Publication Number Publication Date
NO932344D0 NO932344D0 (no) 1993-06-25
NO932344L true NO932344L (no) 1993-06-25
NO304693B1 NO304693B1 (no) 1999-02-01

Family

ID=25908683

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932116A NO304693B1 (no) 1991-10-26 1993-06-25 Kinoksalinderivater med affinitet for quisqualatreseptorer

Country Status (17)

Country Link
EP (1) EP0565683A1 (no)
JP (1) JP3258008B2 (no)
KR (1) KR100262371B1 (no)
CN (1) CN1038840C (no)
AU (1) AU664212B2 (no)
CA (1) CA2099270A1 (no)
CZ (1) CZ286351B6 (no)
FI (1) FI932959A (no)
HU (1) HUT64756A (no)
IL (1) IL103538A (no)
NO (1) NO304693B1 (no)
NZ (1) NZ244896A (no)
PL (1) PL171125B1 (no)
PT (1) PT101004B (no)
RU (1) RU2117663C1 (no)
SK (1) SK281518B6 (no)
WO (1) WO1993008173A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
ES2313714T3 (es) * 1992-06-22 2009-03-01 The Regents Of The University Of California Antagonistas de receptores de glicina y uso de los mismos.
DE4314592A1 (de) * 1993-04-28 1994-11-03 Schering Ag Benzo(f)chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
DE4428152A1 (de) * 1994-06-22 1996-01-04 Basf Ag Neue Amido-chinoxalindione, ihrer Herstellung und Verwendung
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
WO1996010023A1 (fr) * 1994-09-27 1996-04-04 Yamanouchi Pharmaceutical Co., Ltd. Derive de 1,2,3,4-tetrahydroquinoxalindione
DE4439493A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
DE19521058A1 (de) * 1995-06-09 1996-12-12 Basf Ag Verfahren zur Herstellung von Aromaten enthaltenden Polyetherpolyolen
DE19545251A1 (de) * 1995-11-24 1997-05-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
DE19624808A1 (de) 1996-06-21 1998-01-02 Basf Ag Pyrrolylchinoxalindione, ihre Herstellung und Verwendung
DE19728326A1 (de) * 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
EP0900567A3 (en) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
FR2769309B1 (fr) 1997-10-08 2001-06-15 Oreal Composition de teinture d'oxydation des fibres keratiniques comprenant un derive d'aminoacide en tant que base d'oxydation et nouveaux derives d'aminoacides
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118982A1 (en) * 1983-02-01 1984-09-19 Sumitomo Chemical Company, Limited Organic phosphorous quinoxalinone and their production and use
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
DK69790D0 (da) * 1990-03-16 1990-03-16 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling af anvendelse

Also Published As

Publication number Publication date
PT101004A (pt) 1994-01-31
AU664212B2 (en) 1995-11-09
CN1038840C (zh) 1998-06-24
NO932344D0 (no) 1993-06-25
IL103538A0 (en) 1993-03-15
PT101004B (pt) 1999-10-29
NZ244896A (en) 1995-07-26
CZ286351B6 (cs) 2000-03-15
IL103538A (en) 2001-07-24
KR100262371B1 (ko) 2000-08-01
RU2117663C1 (ru) 1998-08-20
KR930703271A (ko) 1993-11-29
PL299929A1 (en) 1994-04-05
CN1072929A (zh) 1993-06-09
SK281518B6 (sk) 2001-04-09
AU2889492A (en) 1993-05-21
JPH06503583A (ja) 1994-04-21
NO304693B1 (no) 1999-02-01
FI932959A0 (fi) 1993-06-24
PL171125B1 (pl) 1997-03-28
HU9301877D0 (en) 1993-09-28
FI932959A (fi) 1993-06-24
JP3258008B2 (ja) 2002-02-18
WO1993008173A1 (de) 1993-04-29
SK72793A3 (en) 1993-10-06
EP0565683A1 (de) 1993-10-20
CZ138793A3 (en) 1994-01-19
HUT64756A (en) 1994-02-28
CA2099270A1 (en) 1993-04-27

Similar Documents

Publication Publication Date Title
NO932344L (no) Kinoksalinderivater med affinitet for quisqualatreseptorer
DE59208415D1 (de) 3-Hydroxy-4-aryl-5-oxo-pyrazolin Derivate
ATE182147T1 (de) Substituierte thiazolidindion derivate
DE69208877D1 (de) Chinuclidinderivate
NO922182L (no) Krystallinske oksatiolan-derivater
EP0442878A4 (en) Derivatives of tryptophan as cck antagonists
FI925763A0 (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
DK0449079T3 (da) Hydantoinderivater
TR26336A (tr) SüBSTITüE EDILMIS PIRAZOLIN TüREVLERI
DE69222599D1 (de) Cephalosporin-Derivate
NO922521D0 (no) Piperidinyletanolderivater med terapeutisk virkning
LV10448A (lv) Piperazinilkamparsulfoniloksitocina antagonista aizvietotie amidu atvasinajumi
FI925469A (fi) Tiazolylsubstituerade kinolylymetoxifenylaettiksyraderivat
BR9205939A (pt) Derivados de 4-aril-3-(heteroalilureído)quinolina
MX9206710A (es) Derivados de piridinol
FI971854A (fi) Substituoituja tetrasyklisiä atsepiinijohdannaisia, joilla on 5-HT2-reseptoriaffiniteetti
DE69222983D1 (de) Heterocyclische Derivate
KR930702353A (ko) 2- 카르바페넴 유도체
FI102546B1 (fi) Menetelmä ergoliinijohdannaisten valmistamiseksi
DE69227554D1 (de) Indolinospirobenzopyran-derivate
BG97117A (bg) Цефалоспоринови производни
BR1100452A (pt) Derivados do bifenilmetilimidazol
BG97241A (bg) Триазолпиримидин производни
SE8800294D0 (sv) Justeranordning for gangjern
SE9101951D0 (sv) New bicyclic morpholine derivatives

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN APRIL 2003